Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Protein-protein interactions are difficult therapeutic targets, and inhibiting pathologically relevant interactions without disrupting other essential ones presents an additional challenge. Herein we report how this might be achieved for the potential anticancer target, the TPX2-importin-α interaction. Importin-α is a nuclear transport protein that regulates the spindle assembly protein TPX2. It has two binding sites--major and minor-to which partners bind. Most nuclear transport cargoes use the major site, whereas TPX2 binds principally to the minor site. Fragment-based approaches were used to identify small molecules that bind importin-α, and crystallographic studies identified a lead series that was observed to bind specifically to the minor site, representing the first ligands specific for this site. Structure-guided synthesis informed the elaboration of these fragments to explore the source of ligand selectivity between the minor and major sites. These ligands are starting points for the development of inhibitors of this protein-protein interaction.

Original publication

DOI

10.1002/cmdc.201500014

Type

Journal article

Journal

ChemMedChem

Publication Date

07/2015

Volume

10

Pages

1232 - 1239

Keywords

cancer, fragment-based ligand design, nuclear transporters, protein-protein interactions, structure-guided ligand design, Binding Sites, Cell Cycle Proteins, Humans, Ligands, Microtubule-Associated Proteins, Models, Molecular, Molecular Structure, Nuclear Proteins, Protein Binding, Small Molecule Libraries, alpha Karyopherins